Combined treatment of vitamin K and teriparatide on bone metabolism and biomechanics in rats with osteoporosis
Published online on: November 1, 2017
Copyright: © Huang et al.
This is an open access article distributed under the terms of Creative Commons Attribution License.
Postmenopausal osteoporosis is a degenerative disease caused by lack of estrogen whereby bone degeneration exceeds bone formation, resulting in loss of bone mass. Various drugs have been utilized in an attempt to ameliorate bone strength in such patients. The aim of the present study was to compare the effects of vitamin K or teriparatide alone and combined on bone metabolism and biomechanics in rats with osteoporosis. The ovaries of rats were excised to construct a rat model of osteoporosis. Rats were subjected to oral intake of vitamin K or subcutaneous injection of teriparatide or both for 8 weeks. ELISA was used to detect the content of carboxylated‑type of osteocalcin (Gla‑OC) and C‑telopeptide of type I collagen (CTX‑I) in serum. Bone density of shaft of femur and metaphyseal bone was measured. Three‑point bending test was performed to analyze the load‑deformation curve of femur. Undecalcified sections of femur were stained with toluidine blue to measure bone histomorphometric static, dynamic and bone resorption parameters. Compared with monotherapy, vitamin K combined with teriparatide significantly increased serum Gla‑OC level and the number of osteoblast, decreased serum CTX‑I level, reduced the number of osteoclasts and increased bone density and strength. This study showed that the efficacy of vitamin K combined with teriparatide is better than that of monotherapy. This combined treatment can promote bone formation, inhibit bone degradation, and improve bone density and strength.